Agilon Health (NYSE:AGL) Hits New 1-Year High – Should You Buy?

Agilon Health, Inc. (NYSE:AGL)’s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $90.48 and last traded at $86.4310, with a volume of 399530 shares. The stock had previously closed at $81.73.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on AGL shares. Citigroup reaffirmed a “neutral” rating and set a $80.00 target price (up from $18.75) on shares of Agilon Health in a report on Friday. TD Cowen reaffirmed a “hold” rating and set a $55.00 target price (up from $17.00) on shares of Agilon Health in a report on Monday, May 11th. Robert W. Baird boosted their price target on shares of Agilon Health from $20.00 to $35.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Barclays lowered their price target on shares of Agilon Health from $25.00 to $12.50 and set an “underweight” rating on the stock in a research report on Friday, February 27th. Finally, Wall Street Zen raised shares of Agilon Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $45.05.

Agilon Health Stock Performance

The firm’s 50-day moving average price is $26.74 and its two-hundred day moving average price is $20.61. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.04 and a current ratio of 1.04. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -4.01 and a beta of 2.29.

Agilon Health (NYSE:AGL) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.04 by $0.76. The firm had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.38 billion. Agilon Health had a negative net margin of 6.09% and a negative return on equity of 146.03%. On average, analysts expect that Agilon Health, Inc. will post -4.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Alpine Global Management LLC acquired a new position in Agilon Health in the fourth quarter valued at about $84,000. Invesco Ltd. lifted its position in Agilon Health by 30.7% in the fourth quarter. Invesco Ltd. now owns 1,004,266 shares of the company’s stock valued at $692,000 after buying an additional 235,951 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in Agilon Health in the fourth quarter valued at about $86,000. Numerai GP LLC lifted its position in Agilon Health by 207.3% in the fourth quarter. Numerai GP LLC now owns 1,228,071 shares of the company’s stock valued at $846,000 after buying an additional 828,472 shares during the last quarter. Finally, Odyssean LLC acquired a new position in Agilon Health in the fourth quarter valued at about $96,000.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.